Ramesh Arjunji, Phd Email & Phone Number

Philadelphia, PA, US

Parsippany, New Jersey, United States

Evidence Synthesis (ES) helps to support the value proposition and lifecycle management for an asset by proactively conceptualizing, designing, collecting, and synthesizing “patient-centric” data and convert it to useable, actionable, and pertinent knowledge for patients, physicians, regulators, payers, HTAs, investors, and policy makers. An actionable ES.

Cambridge, Massachusetts, United States

For lysosomal storage disorders (LSDs) pipeline (Fabry, Gaucher Type I & III, Cystinosis, Pompe, Hunter Syndrome), I translated the unmet medical needs, disease biology, preclinical knowledge, lentiviral gene therapy MOA, stem cell biology, KOL inputs, existing real-world evidence (RWE), available regulatory guidelines and pathways, and.

Bannockburn, IL

I managed a cross-functional team that delivered the support and rationale for $2.125M price for one-time treatment with Zolgensma for Spinal Muscular Atrophy (SMA) by engagement with ICER (Institute for Clinical and Economic Review). Worked with AveXis and Novartis corporate communications to convey the use of higher cost-effectiveness thresholds for.

Upper Providence, Pennsylvania, United States

I advocated for early diagnosis and apheresis (before 1st line treatment) for NY-ESO eligible NSCLC patients (~2% of NSCLC population) for 3rd line treatment with the cell and gene therapy to increase success rate of drug administration and to prepare the patients, physicians, and payers from a reimbursement viewpoint and community-based follow-up care.

Fort Worth, Texas, United States

To address the declining revenue growth rate for Alcon (Revenue ~$10B, annual growth rate less than 10%), I developed a novel method, using the detailed, monthly financial data on 78 business units (business units from pharmaceutical, surgical, and vision care franchises, subgroups within franchises, and six areas, globally) to rank-order the business.

Lawrenceville, New Jersey, United States

Partnered with Global Commercialization, Market Access & Pricing, Health Outcomes, and country-level affiliates for oncology and immunology pipeline assets to conduct primary and secondary payer research and deliver insights that drove decision making.

Weston, Massachusetts, United States

I developed an innovative budget impact model (received an Innovation Award for my efforts from the Chief Commercial Officer) that enabled the national and regional account directors to retain Avonex as the interferon therapy of choice in the formulary for MS patients in the US. The model, which is disease agnostic, was adopted by a large PBM for its.

Collegeville, Pennsylvania, United States

I analyzed NHANES data using SAS software (developed my own code for data analyses) to support business development and early clinical development to treat obesity-diabetes. My analysis showed that the potential market to treat obesity-diabetes could be more than doubled if the BMI threshold were lowered from the original benchmark of greater than 30 to.

Hawthorne, New York, United States

I developed a pricing model for neratinib plus capecitabine versus trastuzumab for HER2+ breast cancer that was well received by the manufacturer, Wyeth. The pricing model showed that the price of neratinib could be increased when capecitabine became a generic, a counter-intuitive result (neratinib was subsidizing the price of branded capecitabine and the.

Chadds Ford, Pennsylvania, United States

I demonstrated the value of “mirrored sales territories” using past, historical call plan data where hospital sales representatives and specialty sales representatives engaged in dual coverage. The analysis led to Endo contracting with an external agency to expand salesforce size from 700+ to 950+.As part of business development, I performed a preliminary.

Horsham, Pennsylvania, United States

I developed a value-based pricing approach (well before VBP was defined) within a month for an in-licensed indication, AA Amyloidosis, a rare condition, using glomerular filtration rate from clinical trial data and quality of life associated with loss of kidney function from secondary data sources. The value-based price recommended by the team was accepted.

Doctor Of Philosophy - Phd, Management Science

Master Of Science - Ms, Mechanical Engineering

Bachelor Of Technology - Btech, Aeronautics/Aviation/Aerospace Science And Technology, General